[Featured Stock] Precision Bio Rises on Spotlight for 20-Minute On-Site COVID-19 Diagnostic Kit Export

[Asia Economy Reporter Minwoo Lee] Precision Bio's stock price is on the rise. Amid the resurgence of COVID-19, news highlighting the company's active business activities, including exporting on-site diagnostic kits, appears to have drawn attention.

As of 10:19 AM on the 9th, Precision Bio's stock price recorded 18,000 KRW, up 4.96% compared to the previous day. With the government deciding to raise the social distancing level in the metropolitan area to Level 4 for two weeks starting from the 12th, the export business of on-site diagnostic kits seems to have been spotlighted due to the rapid resurgence of COVID-19.

Earlier, at the end of last year, Precision Bio announced that its COVID-19 diagnostic kit 'ExDia COVID-19 Ag' was registered by the Swiss health authority as a product usable outside of testing institutions. This product uses nasopharyngeal swabs collected by inserting a swab into the nose as specimens to confirm COVID-19 infection, and results can be confirmed within an average of 20 minutes.

In addition, Precision Bio is selling COVID-19 diagnostic products overseas, including in Europe such as Germany, Austria, and the Czech Republic.

Meanwhile, on the 9th, Prime Minister Kim Boo-kyum announced the plan to raise social distancing to Level 4 at a Central Disaster and Safety Countermeasure Headquarters meeting held at the Government Seoul Office. This was due to the resurgence becoming visible, with about 500 confirmed cases occurring for three consecutive days in Seoul alone.

When raised to Level 4, private gatherings are limited to up to 2 people after 6 PM, and gatherings of 3 or more people are prohibited. Before 6 PM, private gatherings of up to 4 people are allowed. Additionally, the easing measures applied to vaccinated individuals will be suspended.

This content was produced with the assistance of AI translation services.